1628830-21-6 Usage
General Description
GSK3359088 is a chemical compound developed by GlaxoSmithKline for the treatment of advanced solid tumors, including renal cell carcinoma and non-small cell lung cancer. It is a selective small molecule inhibitor of anaplastic lymphoma kinase (ALK) and currently being investigated in clinical trials as a potential targeted therapy for ALK-positive tumors. Preclinical studies have shown promising anti-tumor activity and favorable safety profile for GSK3359088, making it a potential candidate for the treatment of ALK-driven cancers. Further clinical studies are needed to evaluate its efficacy and safety in patients with advanced solid tumors.
Check Digit Verification of cas no
The CAS Registry Mumber 1628830-21-6 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,6,2,8,8,3 and 0 respectively; the second part has 2 digits, 2 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 1628830-21:
(9*1)+(8*6)+(7*2)+(6*8)+(5*8)+(4*3)+(3*0)+(2*2)+(1*1)=176
176 % 10 = 6
So 1628830-21-6 is a valid CAS Registry Number.
1628830-21-6Relevant articles and documents
CARM1 INHIBITORS AND USES THEREOF
-
, (2016/04/09)
Provided herein are compounds of Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein X, R1, R1a, R2a, R2b, R2c, R2d, are as defined herein, and Ring HET is a 6-membered monocyclic heteroaryl ring system of Formula: wherein L2, R13, G8, G10, G11, and G12 are as defined herein. Compounds of the present invention are useful for inhibiting CARMl activity. Methods of using the compounds for treating CARMl -mediated disorders are also described.
